Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
| Buy | Overweight | Hold | Underweight | Sell |
|---|---|---|---|---|
| 3 | 0 | 1 | 0 | 0 |
Analyst Firms Making Recommendations1
- Maxim Group
- Dawson James
- HC Wainwright & Co.
- Aegis Capital
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Kintara Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 07/14/2023 | KTRA | Buy Now | Kintara Therapeutics | $0.36 | 3799.72% | Maxim Group | Jason McCarthy | → $14 | Upgrade | Hold → Buy | Get Alert |
| 09/29/2022 | KTRA | Buy Now | Kintara Therapeutics | $0.36 | — | Maxim Group | Jason McCarthy | — | Downgrade | Buy → Hold | Get Alert |
| 05/16/2022 | KTRA | Buy Now | Kintara Therapeutics | $0.36 | — | Dawson James | Jason Kolbert | — | Downgrade | Buy → Neutral | Get Alert |
| 01/20/2022 | KTRA | Buy Now | Kintara Therapeutics | $0.36 | 735.65% | HC Wainwright & Co. | Michael King | $300 → $150 | Maintains | Buy | Get Alert |
| 09/30/2021 | KTRA | Buy Now | Kintara Therapeutics | $0.36 | 1292.76% | Aegis Capital | Nathan Weinstein | — | Maintains | Buy | Get Alert |
| 09/28/2021 | KTRA | Buy Now | Kintara Therapeutics | $0.36 | 1571.31% | HC Wainwright & Co. | Michael King | — | Initiates | → Buy | Get Alert |
| 02/03/2021 | KTRA | Buy Now | Kintara Therapeutics | $0.36 | 1849.86% | Aegis Capital | Nathan Weinstein | — | Maintains | Buy | Get Alert |
What is the target price for Kintara Therapeutics (KTRA)?
The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Maxim Group on July 14, 2023. The analyst firm set a price target for $14.00 expecting KTRA to rise to within 12 months (a possible 3783.50% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kintara Therapeutics (KTRA)?
The latest analyst rating for Kintara Therapeutics (NASDAQ: KTRA) was provided by Maxim Group, and Kintara Therapeutics upgraded their buy rating.
When is the next analyst rating going to be posted or updated for Kintara Therapeutics (KTRA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kintara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kintara Therapeutics was filed on July 14, 2023 so you should expect the next rating to be made available sometime around July 14, 2024.
Is the Analyst Rating Kintara Therapeutics (KTRA) correct?
While ratings are subjective and will change, the latest Kintara Therapeutics (KTRA) rating was a upgraded with a price target of $0.00 to $14.00. The current price Kintara Therapeutics (KTRA) is trading at is $0.36, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.